Fat Mass clinical trials

Explore recruiting fat mass clinical trials.

Recruiting fat mass studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fat Mass trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion

Austria

Therapeutic use (Phase IV) EU CTIS Study details

Weight management with orismilast alone or in combination with s.c. semaglutide (WELOSITI)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

Czechia, Portugal, Italy, Germany, Poland, Belgium +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) once weekly versus placebo in participants with obesity

Denmark, Belgium, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Fat Mass trials by city

Fat Mass in Toronto Fat Mass in Vancouver Fat Mass in Montreal Fat Mass in Calgary Fat Mass in Edmonton Fat Mass in Ottawa Fat Mass in Winnipeg Fat Mass in Quebec City Fat Mass in Hamilton Fat Mass in Kitchener Fat Mass in London Fat Mass in Halifax Fat Mass in New York Fat Mass in Los Angeles Fat Mass in Chicago Fat Mass in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease